Skip to main content
Premium Trial:

Request an Annual Quote

CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests

NEW YORK (GenomeWeb) – CellMax Life and IncellDx said today that they have signed an agreement to jointly develop and market circulating tumor cell tests across multiple solid tumors and indications, including personalized therapy selection and monitoring.

Under the agreement, CellMax will combine its technology for CTC isolation with IncellDx’s proprietary BioINK microfluidic reagents. Tests will be processed at CellMax's CLIA lab in Sunnyvale, California and will be jointly marketed in the US by its sales force.

Additional terms of the agreement were not disclosed.

CellMax CEO Atul Sharan said in a statement that IncellDx's reagent platform will bring "tremendous added value" to its tests. The first project will be to commercialize a blood-based PD-L1 assay based on analysis of both RNA and protein in captured CTCs, to be used in immunotherapy selection and monitoring.

The first generation of tests developed to measure PD-L1 required a biopsy sample of a patient's tumor. Because blood-based testing is less invasive, easier, and can be performed repeatedly, it offers potential advantages over available assays.

CellMax and IncellDx intend to present performance data for their CTC-based PD-L1 test in non-small cell lung cancer at the annual meeting of the American Association for Cancer Research later this month.

According to the companies, the CellMax technology has been able to capture CTCs for PD-L1 testing in about 90 percent of patients across all stages of NSCLC, with about 50 percent testing PD-L1 positive.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.